Note 2 - Revenue

12 Months Ended

Dec. 31, 2022

Revenue Recognition [Abstract]

Revenue

Revenue

The Company recorded the following revenues for the years ended December 31 (in thousands):

	2022		2021		2020
Product sales, net:
ORLADEYO	$	249,689	$	121,865	$	133
RAPIVAB	15,156		7,231		483
Peramivir	2,865		7,254		2,685
Total product sales, net	267,710		136,350		3,301
Royalty revenue	2,903		(100)		3,381
Milestone revenue	—		15,000		—
Collaborative and other research and development revenues:
U.S. Department of Health and Human Services	190		5,920		9,231
Other Collaborations	24		—		—
Torii Pharmaceutical Co., Ltd.	—		—		1,899
Total collaborative and other research and development revenues	214		5,920		11,130
Total revenues	$	270,827	$	157,170	$	17,812

Royalty revenue from sales of ORLADEYO in Japan by our collaborative partner, Torii, were $1,944 and $690 for the years ended December 31, 2022 and 2021, respectively.